Literature DB >> 16472711

Goals of Treatment for Patients with Metastatic Breast Cancer

Ian Smith1.   

Abstract

The key goal in the treatment of metastatic breast cancer is to prolong survival, with an emphasis on restricting treatment-related toxicity as much as possible. Despite the plethora of treatment modalities available in metastatic breast cancer, significant survival differences are relatively uncommon. Symptom relief and quality of life are other important, clinically validated measurement instruments. Symptom relief in particular is not used as widely used as it could be, in contrast to lung cancer where it has been proven clinically informative. Finally, time to disease progression is an increasingly used primary endpoint in comparing treatments for metastatic breast cancer; this measure includes both patients who achieve an objective response, and those whose disease may be stabilized with treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16472711     DOI: 10.1053/j.seminoncol.2005.07.030

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  22 in total

Review 1.  Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.

Authors:  Isabel Echavarria; Yolanda Jerez; Miguel Martin; Sara López-Tarruella
Journal:  Breast Care (Basel)       Date:  2017-10-19       Impact factor: 2.860

2.  Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills.

Authors:  J Graf; E Simoes; K Wißlicen; L Rava; C B Walter; A Hartkopf; L Keilmann; A Taran; S Wallwiener; P Fasching; S Y Brucker; M Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-05       Impact factor: 2.915

Review 3.  Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?

Authors:  Raffaella Palumbo; Federico Sottotetti; Antonio Bernardo
Journal:  Ther Adv Med Oncol       Date:  2016-04-19       Impact factor: 8.168

4.  DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment.

Authors:  Fernanda Faião-Flores; José Agustín Quincoces Suarez; Paulo Celso Pardi; Durvanei Augusto Maria
Journal:  Tumour Biol       Date:  2011-12-23

5.  Coping resources and self-rated health among Latina breast cancer survivors.

Authors:  Anna M Nápoles; Carmen Ortíz; Helen O'Brien; Andrea B Sereno; Celia P Kaplan
Journal:  Oncol Nurs Forum       Date:  2011-09       Impact factor: 2.172

Review 6.  Oral vinorelbine: role in the management of metastatic breast cancer.

Authors:  Matti S Aapro; Pierfranco Conte; Emilio Esteban González; Véronique Trillet-Lenoir
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Bevacizumab treatment for advanced breast cancer.

Authors:  Ricardo H Alvarez; Valentina Guarneri; Fikri Icli; Stephen Johnston; David Khayat; Sibylle Loibl; Miguel Martin; Christoph Zielinski; PierFranco Conte; Gabriel N Hortobagyi
Journal:  Oncologist       Date:  2011-10-05

8.  A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.

Authors:  A T Brunetto; D Sarker; D Papadatos-Pastos; R Fehrmann; S B Kaye; S Johnston; M Allen; J S De Bono; C Swanton
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

Review 9.  Endpoints in advanced breast cancer: methodological aspects & clinical implications.

Authors:  Everardo D Saad
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

Review 10.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.